Cardiovascular disease and COVID-19 :: les liaisons dangereuses

Andrea Barison; Alberto Aimo; Vincenzo Castiglione; Chiara Arzilli; Josep Lupón; Pau Codina; Evelyn Santiago Vacas; Germán Cediel; Michele Emdin; Antoni Bayés-Genís

doi:10.1177/2047487320924501

Cardiovascular disease and COVID-19 : les liaisons dangereuses

Andrea Barison, Alberto Aimo, Vincenzo Castiglione, Chiara Arzilli, Josep Lupón, Pau Codina, Evelyn Santiago Vacas, Germán Cediel, Michele Emdin, Antoni Bayés-Genís

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

31 Citations (Scopus)

Abstract

Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

Original language	English
Pages (from-to)	1017-1025
Number of pages	9
Journal	European Journal of Preventive Cardiology
Volume	27
Issue number	10
DOIs	https://doi.org/10.1177/2047487320924501
Publication status	Published - 2020

Keywords

COVID-19
Coronavirus
Cardiovascular
Comorbidities
Risk factors
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/2047487320924501

https://ddd.uab.cat/record/244146

Cite this

@article{24671a5923f54ef8b76c76e8b4289e60,

title = "Cardiovascular disease and COVID-19 :: les liaisons dangereuses",

abstract = "Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.",

keywords = "COVID-19, Coronavirus, Cardiovascular, Comorbidities, Risk factors, SARS-CoV-2",

author = "Andrea Barison and Alberto Aimo and Vincenzo Castiglione and Chiara Arzilli and Josep Lup{\'o}n and Pau Codina and {Santiago Vacas}, Evelyn and Germ{\'a}n Cediel and Michele Emdin and Antoni Bay{\'e}s-Gen{\'i}s",

year = "2020",

doi = "10.1177/2047487320924501",

language = "English",

volume = "27",

pages = "1017--1025",

number = "10",

}

TY - JOUR

T1 - Cardiovascular disease and COVID-19 :

T2 - les liaisons dangereuses

AU - Barison, Andrea

AU - Aimo, Alberto

AU - Castiglione, Vincenzo

AU - Arzilli, Chiara

AU - Lupón, Josep

AU - Codina, Pau

AU - Santiago Vacas, Evelyn

AU - Cediel, Germán

AU - Emdin, Michele

AU - Bayés-Genís, Antoni

PY - 2020

Y1 - 2020

N2 - Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

AB - Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

KW - COVID-19

KW - Coronavirus

KW - Cardiovascular

KW - Comorbidities

KW - Risk factors

KW - SARS-CoV-2

U2 - 10.1177/2047487320924501

DO - 10.1177/2047487320924501

M3 - Review article

C2 - 32391719

SN - 2047-4873

VL - 27

SP - 1017

EP - 1025

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

IS - 10